STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Clinical trials for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare liver cancer: Triple-Drug attack shows promise
Disease control Recruiting nowThis study tests a combination of three drugs—nivolumab (an immunotherapy), fluorouracil (chemotherapy), and interferon alpha 2b (immune booster)—in people with a rare type of liver cancer called fibrolamellar carcinoma that cannot be surgically removed. The goal is to see if the…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
Liver cancer hope: combo therapy may boost survival after first treatment fails
Disease control Recruiting nowThis study is for people with advanced liver cancer that cannot be removed by surgery and has gotten worse after initial treatment with atezolizumab plus bevacizumab. Researchers want to see if adding another immunotherapy drug (atezolizumab) to a standard targeted therapy pill (…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated May 16, 2026 23:48 UTC
-
New combo therapy aims to boost immune attack on untreatable liver tumors
Disease control Recruiting nowThis study is for people with advanced liver cancer that cannot be removed by surgery. It tests whether injecting a patient's own specially trained immune cells (dendritic cells) into the tumor, along with immunotherapy drugs, after high-dose radiation is safe and can help contro…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 16, 2026 23:37 UTC
-
New drug duo targets hard-to-treat liver cancer in early trial
Disease control Recruiting nowThis study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific change in the β-catenin gene. The goal is to find the best dose and see if the combination can slow or stop tumor growth better than cabozantinib alone. Ab…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Radiation boosts immunotherapy in advanced liver cancer? new trial aims to find out
Disease control Recruiting nowThis study is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs alone versus immunotherapy plus precise, high-dose radiation (SBRT) to the liver tumor. The goal is to see if adding radiation helps patients live…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for advanced liver cancer: immune drugs after radiation show promise
Disease control Recruiting nowThis study is for people with advanced liver cancer that has spread. It tests whether giving two immune-boosting drugs (durvalumab with or without tremelimumab) after a short course of radiation can help shrink tumors. About 21 participants will receive radiation followed by the …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mary Feng, MD • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Could a common painkiller boost immunotherapy in liver cancer?
Disease control Recruiting nowThis study tests whether adding celecoxib (a pain reliever) to standard immunotherapy drugs (durvalumab and tremelimumab) can help control advanced liver cancer that has spread. About 39 adults with advanced or metastatic hepatocellular carcinoma will receive the combination. The…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Electric field device shows promise in taming advanced cancers
Disease control Recruiting nowThis early-phase study tests a wearable device that creates low-intensity electric fields (tumor treating fields) combined with either cabozantinib or a chemo-immunotherapy pair (nab-paclitaxel and atezolizumab) in people with advanced solid tumors in the abdomen or chest. The go…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Radiation boosts immune attack on stubborn GI cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are spreading and no longer responding to immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system fight cancer throughout the body. About 28 participants will …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New drug AU409 enters first human tests for tough liver cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called AU409 in people with advanced liver cancer or other cancers that have spread to the liver. The main goals are to find the safest dose and see what side effects occur. About 36 adults whose cancer has not responded to standard treatme…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Symptom relief Recruiting nowThis study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 16, 2026 23:47 UTC
-
Scientists use special microscope to peek inside tumors during surgery
Knowledge-focused Recruiting nowThis study uses a special microscope called intravital microscopy (IVM) to watch blood vessels inside solid tumors in real time during surgery. Researchers want to understand how these vessels work, which could help decide if a patient's tumor is likely to respond to certain trea…
Matched conditions: STAGE IV HEPATOCELLULAR CARCINOMA AJCC V8
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 15, 2026 11:55 UTC